Pramipexole is a synthetic non ergot dopamine agonist with high selectivity for D2, D3, and D4 dopamine receptor subtypes and particularly notable for its exceptionally high binding affinity for the D3 receptor subtype relative to D2, a selectivity profile that distinguishes it from older dopamine agonists and has made it a frequently studied reference compound in D3 receptor pharmacology research. FDA approved for Parkinson’s disease and restless legs syndrome, Pramipexole contributes a well documented human clinical literature base spanning neurology, psychiatry, and endocrine research contexts. This formulation delivers 0.25mg per tablet in a 100 count format, a precise low dose presentation suited to the conservative titration based research protocols typical of dopaminergic compound research.

Within the context of CSD’s Estrogen & Prolactin research range, Pramipexole’s most research relevant activity is its D2 receptor agonism at the pituitary lactotroph level. Prolactin secretion from anterior pituitary lactotroph cells is tonically inhibited by dopamine through D2 receptor activation. The same pathway through which endogenous dopamine suppresses prolactin release. Pramipexole’s D2 receptor agonism mimics this inhibitory dopamine signal, producing prolactin suppression through direct pituitary dopaminergic pathway activation. This prolactin lowering mechanism makes Pramipexole a frequently studied compound in research examining hyperprolactinaemia models, prolactin mediated HPG axis suppression, and the dopaminergic regulation of pituitary hormone secretion. A pharmacological application directly relevant to its placement in the Estrogen & Prolactin research category.

Pramipexole’s D3 receptor selectivity adds a second distinct research dimension beyond prolactin regulation. D3 receptors are concentrated in limbic system structures, nucleus accumbens, olfactory tubercle, and ventral striatum. Making D3 selective dopamine agonism a subject of significant research interest in reward pathway modulation, mood regulation, and impulse control research. The combination of D2 mediated prolactin suppression and D3 mediated limbic dopaminergic activity in a single compound makes Pramipexole a versatile research tool spanning neuroendocrinology and neuropsychiatry research contexts simultaneously. Dual research profile that distinguishes it from prolactin suppressing compounds that operate exclusively through hormonal or receptor pathways outside the dopaminergic system.

Every batch of CSD’s Pramipexole is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our Estrogen & Prolactin range covers dopaminergic prolactin regulation alongside SERM and aromatase inhibitor estrogen management research from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store in a cool, dry place away from direct light and heat. Intended for research purposes only.

Commonly researched alongside Cabergoline in comparative dopamine agonist and prolactin regulation studies. Browse CSD’s full hormone research range for complete sourcing.